Targets › CSFR3
1 program from 1 company in 1 trial: 1 Phase 2; Hematology; next expected readout Oct 2027.
Open in Phaseline: the race on CSFR3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Henan Cancer Hospital | Efbemalenograstim alfa Granulocyte colony-stimulating factor (G-CSF) receptor agonist | CSFR3 | Phase 2 | Primary/Secondary Prevention | Oct 2027 |
Primary/Secondary Prevention (1)
protein or peptide (1)
Henan Cancer Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.